Concepts (179)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Internship and Residency | 2 | 2025 | 803 | 0.970 |
Why?
|
| Translations | 1 | 2026 | 8 | 0.960 |
Why?
|
| Translating | 1 | 2026 | 21 | 0.950 |
Why?
|
| Clinical Clerkship | 1 | 2026 | 94 | 0.910 |
Why?
|
| Simulation Training | 1 | 2026 | 66 | 0.900 |
Why?
|
| Communication Barriers | 1 | 2026 | 70 | 0.900 |
Why?
|
| Health Equity | 1 | 2026 | 55 | 0.890 |
Why?
|
| Social Media | 3 | 2025 | 128 | 0.870 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2026 | 162 | 0.860 |
Why?
|
| Emergency Medicine | 1 | 2026 | 194 | 0.800 |
Why?
|
| Artificial Intelligence | 1 | 2026 | 213 | 0.740 |
Why?
|
| Patient Education as Topic | 1 | 2026 | 488 | 0.730 |
Why?
|
| Patient Discharge | 1 | 2026 | 521 | 0.720 |
Why?
|
| Curriculum | 1 | 2026 | 610 | 0.720 |
Why?
|
| Students, Medical | 1 | 2025 | 265 | 0.710 |
Why?
|
| Emergency Service, Hospital | 2 | 2026 | 1161 | 0.550 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2018 | 142 | 0.480 |
Why?
|
| Pharmaceutical Preparations | 1 | 2017 | 125 | 0.460 |
Why?
|
| Respiratory Center | 1 | 2013 | 3 | 0.400 |
Why?
|
| Organophosphate Poisoning | 1 | 2013 | 14 | 0.390 |
Why?
|
| Respiratory Insufficiency | 1 | 2013 | 154 | 0.340 |
Why?
|
| Pneumoperitoneum | 1 | 2010 | 4 | 0.330 |
Why?
|
| Colonoscopy | 1 | 2010 | 97 | 0.320 |
Why?
|
| Clinical Competence | 2 | 2026 | 732 | 0.310 |
Why?
|
| Faculty, Medical | 2 | 2023 | 200 | 0.290 |
Why?
|
| Rhode Island | 2 | 2026 | 110 | 0.260 |
Why?
|
| Drug Overdose | 2 | 2019 | 122 | 0.250 |
Why?
|
| Female | 13 | 2026 | 34193 | 0.250 |
Why?
|
| Humans | 20 | 2026 | 65463 | 0.240 |
Why?
|
| Cultural Competency | 1 | 2026 | 58 | 0.240 |
Why?
|
| Poisoning | 3 | 2020 | 27 | 0.230 |
Why?
|
| Ethanol | 2 | 2019 | 333 | 0.230 |
Why?
|
| Inhibin-beta Subunits | 2 | 2003 | 7 | 0.220 |
Why?
|
| Activins | 2 | 2003 | 55 | 0.210 |
Why?
|
| Plant Poisoning | 1 | 2023 | 1 | 0.200 |
Why?
|
| Foodborne Diseases | 1 | 2023 | 6 | 0.200 |
Why?
|
| Androgens | 1 | 2003 | 66 | 0.200 |
Why?
|
| Hallucinogens | 1 | 2023 | 13 | 0.200 |
Why?
|
| Male | 11 | 2026 | 31187 | 0.190 |
Why?
|
| Cannabis | 1 | 2023 | 54 | 0.190 |
Why?
|
| United States | 4 | 2026 | 8148 | 0.170 |
Why?
|
| Toxicology | 2 | 2019 | 22 | 0.170 |
Why?
|
| Education, Medical, Graduate | 1 | 2023 | 348 | 0.160 |
Why?
|
| Prostatic Neoplasms | 2 | 2003 | 498 | 0.150 |
Why?
|
| Sex Factors | 2 | 2019 | 995 | 0.150 |
Why?
|
| Testicular Hormones | 3 | 2003 | 11 | 0.150 |
Why?
|
| Suicide, Attempted | 1 | 2019 | 111 | 0.140 |
Why?
|
| Efficiency | 1 | 2018 | 39 | 0.140 |
Why?
|
| Writing | 1 | 2018 | 43 | 0.140 |
Why?
|
| Glycoproteins | 3 | 2003 | 189 | 0.130 |
Why?
|
| Cross-Sectional Studies | 1 | 2025 | 2721 | 0.130 |
Why?
|
| Social Support | 2 | 2018 | 393 | 0.130 |
Why?
|
| NF-kappa B | 3 | 2004 | 435 | 0.130 |
Why?
|
| Cardiovascular Agents | 1 | 2018 | 107 | 0.130 |
Why?
|
| Systems Integration | 1 | 2017 | 26 | 0.130 |
Why?
|
| Transducers | 1 | 2017 | 23 | 0.130 |
Why?
|
| Glass | 1 | 2017 | 23 | 0.130 |
Why?
|
| Community Networks | 1 | 2017 | 28 | 0.130 |
Why?
|
| Surveys and Questionnaires | 1 | 2025 | 2776 | 0.120 |
Why?
|
| Drug Approval | 1 | 2017 | 28 | 0.120 |
Why?
|
| Morbidity | 1 | 2017 | 110 | 0.120 |
Why?
|
| Registries | 4 | 2023 | 929 | 0.120 |
Why?
|
| United States Food and Drug Administration | 1 | 2017 | 92 | 0.120 |
Why?
|
| Smartphone | 1 | 2017 | 75 | 0.120 |
Why?
|
| Weight Reduction Programs | 1 | 2017 | 63 | 0.120 |
Why?
|
| Body Weight | 1 | 2017 | 376 | 0.110 |
Why?
|
| Adult | 5 | 2025 | 17461 | 0.100 |
Why?
|
| Women's Health | 1 | 2017 | 375 | 0.100 |
Why?
|
| Research Design | 1 | 2017 | 590 | 0.100 |
Why?
|
| Organophosphorus Compounds | 1 | 2013 | 33 | 0.100 |
Why?
|
| Diagnostic Errors | 1 | 2014 | 106 | 0.100 |
Why?
|
| Analgesics, Opioid | 1 | 2018 | 529 | 0.100 |
Why?
|
| Retrospective Studies | 2 | 2023 | 6929 | 0.090 |
Why?
|
| Nerve Net | 1 | 2013 | 103 | 0.090 |
Why?
|
| Telemedicine | 1 | 2017 | 373 | 0.090 |
Why?
|
| Acute Disease | 1 | 2013 | 663 | 0.090 |
Why?
|
| Pneumonia | 1 | 2014 | 295 | 0.090 |
Why?
|
| Intestinal Perforation | 1 | 2010 | 17 | 0.080 |
Why?
|
| Cell Division | 4 | 2003 | 450 | 0.080 |
Why?
|
| Immediate-Early Proteins | 3 | 2004 | 46 | 0.080 |
Why?
|
| Colon | 1 | 2010 | 147 | 0.080 |
Why?
|
| Radiography | 1 | 2010 | 558 | 0.070 |
Why?
|
| Obesity | 1 | 2017 | 1275 | 0.070 |
Why?
|
| S Phase | 2 | 2003 | 79 | 0.060 |
Why?
|
| Breast Neoplasms | 3 | 2004 | 1231 | 0.060 |
Why?
|
| Child, Preschool | 2 | 2023 | 2066 | 0.060 |
Why?
|
| Tumor Cells, Cultured | 2 | 2003 | 426 | 0.060 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2004 | 210 | 0.060 |
Why?
|
| Cell Cycle | 2 | 2003 | 398 | 0.050 |
Why?
|
| Prospective Studies | 2 | 2023 | 3324 | 0.050 |
Why?
|
| E2F Transcription Factors | 1 | 2003 | 16 | 0.050 |
Why?
|
| Smad3 Protein | 1 | 2003 | 17 | 0.050 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2003 | 32 | 0.050 |
Why?
|
| E2F1 Transcription Factor | 1 | 2003 | 18 | 0.050 |
Why?
|
| Retinoblastoma Protein | 1 | 2003 | 45 | 0.050 |
Why?
|
| Neoplasm Proteins | 2 | 2003 | 285 | 0.050 |
Why?
|
| Prostate-Specific Antigen | 1 | 2003 | 84 | 0.050 |
Why?
|
| Psychotropic Drugs | 1 | 2023 | 81 | 0.050 |
Why?
|
| Middle Aged | 4 | 2019 | 18387 | 0.050 |
Why?
|
| Signal Transduction | 2 | 2003 | 3155 | 0.050 |
Why?
|
| Child | 2 | 2023 | 4623 | 0.040 |
Why?
|
| Growth Inhibitors | 1 | 2002 | 24 | 0.040 |
Why?
|
| Trans-Activators | 1 | 2003 | 321 | 0.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2004 | 586 | 0.040 |
Why?
|
| Apoptosis | 2 | 2003 | 1098 | 0.040 |
Why?
|
| Interferon-gamma | 1 | 2003 | 574 | 0.040 |
Why?
|
| Phosphorylation | 1 | 2003 | 962 | 0.040 |
Why?
|
| Cell Cycle Proteins | 1 | 2003 | 403 | 0.040 |
Why?
|
| Adolescent | 2 | 2023 | 6332 | 0.040 |
Why?
|
| Animals | 5 | 2013 | 21381 | 0.040 |
Why?
|
| Prostate | 1 | 2002 | 124 | 0.040 |
Why?
|
| DNA-Binding Proteins | 2 | 2003 | 1225 | 0.040 |
Why?
|
| Sex Distribution | 1 | 2020 | 252 | 0.040 |
Why?
|
| Age Distribution | 1 | 2020 | 262 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2023 | 879 | 0.040 |
Why?
|
| Aged | 4 | 2019 | 15052 | 0.040 |
Why?
|
| Bites and Stings | 1 | 2018 | 10 | 0.040 |
Why?
|
| Research Support as Topic | 1 | 2018 | 42 | 0.030 |
Why?
|
| Anti-Mullerian Hormone | 3 | 2003 | 68 | 0.030 |
Why?
|
| Suicidal Ideation | 1 | 2019 | 133 | 0.030 |
Why?
|
| Polypharmacy | 1 | 2018 | 67 | 0.030 |
Why?
|
| Mentors | 1 | 2018 | 118 | 0.030 |
Why?
|
| Telemetry | 1 | 2017 | 17 | 0.030 |
Why?
|
| Medication Errors | 1 | 2018 | 127 | 0.030 |
Why?
|
| Gene Expression Regulation | 1 | 2003 | 1631 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2020 | 887 | 0.030 |
Why?
|
| Diffusion of Innovation | 1 | 2017 | 67 | 0.030 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2017 | 99 | 0.030 |
Why?
|
| Forecasting | 1 | 2017 | 230 | 0.030 |
Why?
|
| Time Factors | 2 | 2020 | 3774 | 0.030 |
Why?
|
| Equipment Design | 1 | 2017 | 371 | 0.030 |
Why?
|
| Transcription Factors | 1 | 2003 | 1557 | 0.030 |
Why?
|
| Biosensing Techniques | 1 | 2017 | 126 | 0.030 |
Why?
|
| Infant | 1 | 2020 | 1703 | 0.030 |
Why?
|
| Mobile Applications | 1 | 2017 | 140 | 0.030 |
Why?
|
| False Negative Reactions | 1 | 2014 | 41 | 0.030 |
Why?
|
| Hospitals, Urban | 1 | 2014 | 44 | 0.030 |
Why?
|
| Radiography, Thoracic | 1 | 2014 | 117 | 0.030 |
Why?
|
| Internet | 1 | 2017 | 472 | 0.020 |
Why?
|
| Mice, Inbred C3H | 2 | 2003 | 173 | 0.020 |
Why?
|
| Pregnancy | 1 | 2019 | 2390 | 0.020 |
Why?
|
| Apoptosis Regulatory Proteins | 2 | 2003 | 152 | 0.020 |
Why?
|
| Emergency Medical Services | 1 | 2014 | 262 | 0.020 |
Why?
|
| Recombinant Proteins | 2 | 2003 | 706 | 0.020 |
Why?
|
| Rats | 2 | 2004 | 1996 | 0.020 |
Why?
|
| Quality Improvement | 1 | 2014 | 468 | 0.020 |
Why?
|
| Young Adult | 1 | 2019 | 4837 | 0.020 |
Why?
|
| Cell Line, Tumor | 2 | 2003 | 1567 | 0.020 |
Why?
|
| Membrane Proteins | 2 | 2003 | 924 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2014 | 1659 | 0.020 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2004 | 78 | 0.010 |
Why?
|
| Bone Morphogenetic Protein Receptors, Type I | 1 | 2003 | 5 | 0.010 |
Why?
|
| Receptors, Growth Factor | 1 | 2003 | 19 | 0.010 |
Why?
|
| Activin Receptors, Type I | 1 | 2003 | 15 | 0.010 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2003 | 30 | 0.010 |
Why?
|
| NF-kappa B p50 Subunit | 1 | 2003 | 27 | 0.010 |
Why?
|
| Interferon Regulatory Factor-1 | 1 | 2003 | 5 | 0.010 |
Why?
|
| Receptors, Peptide | 1 | 2003 | 34 | 0.010 |
Why?
|
| Transcription Factor RelA | 1 | 2003 | 51 | 0.010 |
Why?
|
| Drug Synergism | 1 | 2003 | 142 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2004 | 624 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2004 | 897 | 0.010 |
Why?
|
| Phosphoproteins | 1 | 2003 | 224 | 0.010 |
Why?
|
| Ribonucleases | 1 | 2002 | 33 | 0.010 |
Why?
|
| Biopsy | 1 | 2003 | 460 | 0.010 |
Why?
|
| Genes, Dominant | 1 | 2002 | 56 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 2002 | 152 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 2002 | 213 | 0.010 |
Why?
|
| CHO Cells | 1 | 2002 | 193 | 0.010 |
Why?
|
| Cricetinae | 1 | 2002 | 363 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2002 | 376 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2002 | 611 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2002 | 513 | 0.010 |
Why?
|
| Gene Expression | 1 | 2003 | 854 | 0.010 |
Why?
|
| Mice | 2 | 2003 | 11138 | 0.010 |
Why?
|
| Membrane Glycoproteins | 1 | 2002 | 662 | 0.010 |
Why?
|
| Models, Biological | 1 | 2002 | 1192 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2002 | 1575 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2003 | 5644 | 0.010 |
Why?
|